PACB - Pacific Biosciences of California Q3 2021 Earnings Preview

Pacific Biosciences of California (NASDAQ:PACB) is scheduled to announce Q3 earnings results on Tuesday, November 2nd, after market close. The consensus EPS Estimate is -$0.24 and the consensus Revenue Estimate is $33.6M (+76.1% Y/Y). Pacific Biosciences shares traded marginally lower despite posting a revenue beat with its Q2 2021 financials, in August. In August, Seeking Alpha contributor Khaveen Investments argued that the company's "long-term growth potential (is) secured with strategic R&D partnerships with Invitae and Asuragen aimed at reducing the cost of genome sequencing". Last month, Canaccord Genuity initiated coverage on Pacific Biosciences with a buy rating and $45 price target. The company's shares have gained more than 2% year to  date.

For further details see:

Pacific Biosciences of California Q3 2021 Earnings Preview